Health and Fitness Health and Fitness
Tue, October 6, 2009
Mon, October 5, 2009

Eurand N.V.: Eurand Announces Conference Call on Third Quarter 2009 Financial Results


Published on 2009-10-05 06:17:08 - Market Wire
  Print publication without navigation


AMSTERDAM, THE NETHERLANDS--(Marketwire - October 5, 2009) - Eurand N.V. (NASDAQ: [ EURX ]), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, will host a conference call on Thursday, November 5, 2009 at 8:30 a.m. ET to discuss its third quarter 2009 financial results. The conference call will be hosted by Gearóid Faherty, Chairman and Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.

 The conference call schedule is as follows: 7:00 a.m. ET: Third quarter 2009 financial results released 8:20 a.m. ET: Dial in to participate in the conference call: -- US Participants dial 1-877-407-9039 -- International Participants dial +1-201-689-8470 8:30 a.m. ET: Conference call begins Call Replay: A replay of the call will be available until December 5, 2009. The Account Number is: 3055; Conference ID Number: 334294. -- US Participants dial 1-877-660-6853 -- International Participants dial +1-201-612-7415 

A live webcast of the call will also be available from the Investor Relations section of the corporate web site at [ www.eurand.com ]. Following the live webcast, the archived version of the call will be available at the same URL until December 5, 2009.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit [ www.eurand.com ].